ArticleAmerican journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists2022
National trends in prescription drug expenditures and projections for 2022.
Article in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Projections of Public Spending on Pharmaceuticals: A Review of Methods.PharmacoEconomics · 2025Pooled it
- Where do people obtain side effect information? Results from a census-matched U.S. national survey.Exploratory research in clinical and social pharmacy · 2026Article
- Cost-Effectiveness of Perioperative Immune Checkpoint Therapy for NSCLC in Japan, the United States, and Brazil.JTO clinical and research reports · 2026Article
- Topic and Sentiment Trends in Semaglutide Discussions on X: Subpopulation-Based Longitudinal Analysis.Online journal of public health informatics · 2026Article
- A model-based cost-effectiveness analysis of prescribing by dietitians and therapeutic radiographers in England.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Out-of-Pocket Spending for Biologic Drugs After Biosimilar Competition for Medicare Patients.JAMA network open · 2026Article
- Exploring the association between pharmacy curricular tracks and students' attitudes toward generic medicines: insights from a comparative study in Egypt.Frontiers in pharmacology · 2026Article
- Glucagon-like peptide-1 receptor agonists and risk for cardiovascular events in older adults treated with levothyroxine: a target trial emulation.Cardiovascular diabetology · 2025Observational
- Horizon scanning and drug expenditure for rare diseases: three-year predictive model in Italy 2025-2027.Health economics review · 2025Article
- The complexity of pharmaceutical expenditures across U.S. states.Scientific reports · 2025Article
- Demographic Variation In US Outpatient Hydroxychloroquine And Ivermectin Use During The COVID-19 Pandemic.Health affairs (Project Hope) · 2025Article
- New Drug Expenditure by Therapeutic Area in South Korea: International Comparison and Policy Implications.Healthcare (Basel, Switzerland) · 2025Article
- Multiple sclerosis patients taking glucagon-like peptide-1 receptor (GLP-1) agonists: a single-institution retrospective cohort study of tolerability and weight loss.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Article
- Development of a decision aid with cost information for heart failure medication in Singapore.PEC innovation · 2024Article
- Association between changes in prices and out-of-pocket costs for brand-name clinician-administered drugs.Health services research · 2024Article
- Budget impact analysis of including biosimilar adalimumab on formulary: A United States payer perspective.Journal of managed care & specialty pharmacy · 2024Article
- A Review of Risk Factors for Polypharmacy: Age, Level of Education, and Physician's Attitude.Cureus · 2024Review
- Impact of VA Hematology/Oncology Clinical Pharmacy Practitioners in the Review of Community Prescriptions for Specialty Medications.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2024Article
- Associations between Diabetes-Specific Medication Regimen Complexity and Cardiometabolic Outcomes among Underserved Non-Hispanic Black Adults Living with Type 2 Diabetes Mellitus.Pharmacy (Basel, Switzerland) · 2024Article
- Role of Specialty Drugs in Rising Drug Prices for Medicare Part D.JAMA health forum · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo report historical patterns of pharmaceutical expenditures, to identify factors that may influence future spending, and to predict growth in drug spending in 2022 in the United States, with a focus on the nonfederal hospital and clinic sectors.
methodsHistorical patterns were assessed by examining data on drug purchases from manufacturers using the IQVIA National Sales Perspectives database. Factors that may influence drug spending in hospitals and clinics in 2022 were reviewed-including new drug approvals, patent expirations, and potential new policies or legislation. Focused analyses were conducted for biosimilars, cancer drugs, generics, COVID-19 pandemic influence, and specialty drugs. For nonfederal hospitals, clinics, and overall (all sectors), estimates of growth of pharmaceutical expenditures in 2022 were based on a combination of quantitative analyses and expert opinion.
resultsIn 2021, overall pharmaceutical expenditures in the US grew 7.7% compared to 2020, for a total of $576.9 billion. Utilization (a 4.8% increase), price (a 1.9% increase) and new drugs (a 1.1% increase) drove this increase. Adalimumab was the top drug in terms of overall expenditures in 2021, followed by apixaban and dulaglutide. Drug expenditures were $39.6 billion (a 8.4% increase) and $105.0 billion (a 7.7% increase) in nonfederal hospitals and in clinics, respectively. In clinics and hospitals, new products and increased utilization growth drove growth, with decreasing prices for both sectors acting as an expense restraint. Several new drugs that are likely to influence spending are expected to be approved in 2022. Specialty and cancer drugs will continue to drive expenditures along with the evolution of the COVID-19 pandemic.
conclusionFor 2022, we expect overall prescription drug spending to rise by 4.0% to 6.0%, whereas in clinics and hospitals we anticipate increases of 7.0% to 9.0% and 3.0% to 5.0%, respectively, compared to 2021. These national estimates of future pharmaceutical expenditure growth may not be representative of any particular health system because of the myriad of local factors that influence actual spending.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.